Axon Enterprise, Inc. (NASDAQ:AXON) Receives Average Rating of “Buy” from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON) has been assigned an average rating of “Buy” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $488.67.

AXON has been the topic of several research analyst reports. Needham & Company LLC upped their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Northland Securities raised their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, Robert W. Baird boosted their price target on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th.

Insider Transactions at Axon Enterprise

In other news, CFO Brittany Bagley sold 4,338 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the transaction, the chief financial officer now directly owns 98,825 shares of the company’s stock, valued at approximately $37,449,733.75. This represents a 4.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Julie A. Cullivan sold 1,261 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total value of $860,077.66. Following the sale, the director now owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. This represents a 34.52 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 103,928 shares of company stock valued at $50,820,792. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock valued at $710,103,000 after acquiring an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in Axon Enterprise by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after purchasing an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after buying an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock worth $224,281,000 after buying an additional 9,090 shares during the period. Finally, Groupama Asset Managment purchased a new stake in shares of Axon Enterprise during the third quarter valued at $200,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 0.8 %

AXON opened at $637.45 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The stock’s 50 day moving average price is $525.87 and its 200-day moving average price is $398.80. Axon Enterprise has a one year low of $235.33 and a one year high of $698.67. The stock has a market cap of $48.61 billion, a price-to-earnings ratio of 164.72, a P/E/G ratio of 15.13 and a beta of 1.01.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.